Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Poly Medicure's net profit margin of 19.2% in FY2025 reflects good profitability, with operating margin at 26.1% and gross margin at 68.5%.
In FY 2025, Poly Medicure posted a gross margin of 68.5%, an operating margin of 26.1%, a net margin of 19.2%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Poly Medicure's revenue grew 22.6% to 17.59B and net profit grew 31.1% to 3.39B YoY in FY2025, indicating strong business momentum.
In FY 2025, Poly Medicure's revenue grew by 22.6% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Poly Medicure's ROE of 12.2% in FY2025 indicates moderate shareholder returns.
In FY 2025, Poly Medicure reported an ROE of 12.2%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Poly Medicure's FCF/NI ratio of -0.27x in FY2025 indicates weak cash generation raising concerns about earnings quality.
In FY 2025, Poly Medicure's free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Poly Medicure's OCF/NI ratio of 0.71x in FY2025 indicates reasonable cash conversion from operations.
In FY 2025, Poly Medicure's operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Poly Medicure's current ratio of 5.18x in FY2025 indicates excessively high liquidity that may signal inefficient asset management.
In FY 2025, Poly Medicure reported a current ratio of 5.18. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Poly Medicure's interest coverage ratio of 38.3x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Poly Medicure reported an interest coverage ratio of 38.3x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Poly Medicure's debt-to-equity ratio of 0.07x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Poly Medicure reported a debt-to-equity ratio of 0.07. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Poly Medicure's debt increased 3.6% YoY in FY2025 — debt levels are increasing.
In FY 2025, Poly Medicure's total debt increased by 3.6% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Poly Medicure's diluted shares increased 3.4% YoY in FY2025 — share dilution.
Over 2 years (FY2024–FY2025), diluted shares increased 3.4% from 96.02M to 99.24M, indicating cumulative dilution.
In FY 2025, Poly Medicure's diluted shares increased by 3.4% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025